Abstract:Critical sized cartilage defects heal poorly and MSC-based therapies holds promise functional cartilage regeneration either used alone or in combination with growth factors. However, Recombinant protein growth factors were proven to have minimal benefits while to have adverse side effects and high cost. Nonviral mRNA delivery provides a promising, alternative approach to delivering therapeutic proteins within defect lesion for an extended period of time. Despite successful therapeutic outcome in bone and other vascularized tissues, the therapeutic application of mRNA in poorly vascularized tissues such as cartilage is still facing many challenges and rarely studied. We report here using chemically modified messenger RNA encoding TGF-β3(TGF-β3 cmRNA) to enhance the therapeutic efficacy of BMSCs to efficient repair of cartilage defect. Local administration of TGF-β3 cmRNA enhanced BMSCs therapy restored critical-sized cartilage defects in situ in a rat model within 6 weeks with structural and molecular markers similar to its nature counterparts. In addition, the development of osteoarthritis caused by cartilage damage was prevented by this mRNA-enhanced BMSCs therapy evidenced by minimal late-stage OA pharmacological presentations. This novel mRNA enhanced-MSC technology extend the development of new therapeutic approaches for treating functional cartilage repair. ### Competing Interest Statement YY received the research funding from:National Nature Science Foundation of China (82002355), Shenzhen Institute of Synthetic Biology Scientific Research Program (Grant No. DWKF20190010, JCHZ20200005), FC received the research funding from: the Shenzhen Institutes of Advanced Technology Innovation Program for Excellent Young Researchers (Y9G075), GeneHeal Medicine-SIAT mRNA Regenerative Medicine Laboratory (E1Z124) . LZ received the research funding from: the National Natural Science Foundation of China [81660364, 81760343], Jiangxi Provincial Department of Education Research Program Major Project (171352), Science and Technology Planning Project of Jiangxi Health Commission (20191025, 202130131). XZ received the research funding National Nature Science Foundation of China (32071341). GW, JH, FY are employee at Gene Heal Medicine, a privately owned company developing mRNA therapeutics.All others have no potential conflict of interest.

A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system

Cartilage-Targeting Mrna-Lipid Nanoparticles Rescue Perifocal Apoptotic Chondrocytes for Integrative Cartilage Repair

Lncrnas: Function and Mechanism in Cartilage Development, Degeneration, and Regeneration

Targeting FAP-positive chondrocytes in osteoarthritis: a novel lipid nanoparticle siRNA approach to mitigate cartilage degeneration

LNP-mRNA Delivers TNF-α Antibody to Deep Cartilage and Protects Against Osteoarthritis

Co‐Polymer Carrier with Dual Advantages of Cartilage‐Penetrating and Targeting Improves Delivery and Efficacy of microRNA Treatment of Osteoarthritis

In situ self imine-crosslinked nanocomplexes loaded with small noncoding RNA for efficient osteoarthritis attenuation

Highly efficient healing of critical sized articular cartilage defect in situ using a chemically nucleoside-modified mRNA-enhanced cell therapy

Intra-articular delivery of anti-Hif-2α siRNA by chondrocyte-homing nanoparticles to prevent cartilage degeneration in arthritic mice

Promoting chondrogenesis by targeted delivery to the degenerating cartilage in early treatment of osteoarthritis

Lipid Nanoparticle-Encapsulated VEGFa Sirna Facilitates Cartilage Formation by Suppressing Angiogenesis

A novel mesenchymal stem cell-targeting dual-miRNA delivery system based on aptamer-functionalized tetrahedral framework nucleic acids: Application to endogenous regeneration of articular cartilage

Precise targeting of miR-141/200c cluster in chondrocytes attenuates osteoarthritis development

Combination of anti-inflammatory therapy and RNA interference by light-inducible hybrid nanomedicine for osteoarthritis treatment

Nanoarchitectonics of Injectable Biomimetic Conjugates for Cartilage Protection and Therapy Based on Degenerative Osteoarthritis Progression

Targeted Therapy of Osteoarthritis via Intra‐Articular Delivery of Lipid‐Nanoparticle‐Encapsulated Recombinant Human FGF18 mRNA

A Novel Nanometer Non-Viral Gene Transfer System for Cartilage Defects

Chondrocyte Membrane–coated Nanoparticles Promote Drug Retention and Halt Cartilage Damage in Rat and Canine Osteoarthritis

Dual-targeted Lipid Nanoparticles System for Synergistic Anti-Inflammation and Cartilage Repair in the Treatment of Temporomandibular Joint Osteoarthritis

A Tetrahedral Framework Nucleic Acids-Based Gene Therapeutic Nanococktail Alleviates Cartilage Damage and Protects Against Osteoarthritis Progression

Development of Targeted Nanoscale Drug Delivery System for Osteoarthritic Cartilage Tissue